NO20093592L - Medication for the treatment of diabetes - Google Patents

Medication for the treatment of diabetes

Info

Publication number
NO20093592L
NO20093592L NO20093592A NO20093592A NO20093592L NO 20093592 L NO20093592 L NO 20093592L NO 20093592 A NO20093592 A NO 20093592A NO 20093592 A NO20093592 A NO 20093592A NO 20093592 L NO20093592 L NO 20093592L
Authority
NO
Norway
Prior art keywords
medication
diabetes
treatment
diabetic
patients
Prior art date
Application number
NO20093592A
Other languages
Norwegian (no)
Inventor
Andrew A Wolff
Marcus Jerling
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20093592L publication Critical patent/NO20093592L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives metoder for å senke nivået av HbAIc i plasma hos diabetes-, prediabetes- og ikke-diabetes-pasienter som lider av minst en kardiovaskulær sykdom, og dette forsinker eller utsetter utviklingen eller forverringen av hyperglykemi hos slike pasienter.Methods are described for lowering plasma HbAIc levels in diabetic, prediabetic and non-diabetic patients suffering from at least one cardiovascular disease and this delays or postpones the development or worsening of hyperglycemia in such patients.

NO20093592A 2007-05-31 2009-12-23 Medication for the treatment of diabetes NO20093592L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/070140 WO2008147417A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Publications (1)

Publication Number Publication Date
NO20093592L true NO20093592L (en) 2010-01-20

Family

ID=38812044

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093592A NO20093592L (en) 2007-05-31 2009-12-23 Medication for the treatment of diabetes

Country Status (11)

Country Link
EP (1) EP2152268A1 (en)
JP (1) JP2010528112A (en)
KR (1) KR20100038322A (en)
CN (1) CN101678017A (en)
AU (1) AU2007354300A1 (en)
BR (1) BRPI0721741A2 (en)
CA (1) CA2687381A1 (en)
IL (1) IL202002A0 (en)
MX (1) MX2009012957A (en)
NO (1) NO20093592L (en)
WO (1) WO2008147417A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (en) * 2018-11-26 2019-06-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Method for prediction of the risk of developing ischemic heart disease in patients with type 2 diabetes mellitus combined with subclinical thyrotoxicosis
CN110812344A (en) * 2019-12-17 2020-02-21 卓和药业集团有限公司 Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
CN101098682A (en) * 2005-01-06 2008-01-02 Cv医药有限公司 Sustained release pharmaceutical formulations comprising ranolazine

Also Published As

Publication number Publication date
BRPI0721741A2 (en) 2013-02-13
KR20100038322A (en) 2010-04-14
WO2008147417A1 (en) 2008-12-04
MX2009012957A (en) 2010-03-03
CA2687381A1 (en) 2008-12-04
AU2007354300A1 (en) 2008-12-04
JP2010528112A (en) 2010-08-19
EP2152268A1 (en) 2010-02-17
CN101678017A (en) 2010-03-24
IL202002A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
Zhernakova et al. Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome
Xue et al. Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation
Graff et al. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment
Huang et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
WO2010049678A3 (en) Treatment of energy utilization diseases
Howes et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance
HK1136943A1 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
MX2010013876A (en) Aryl gpr119 agonists and uses thereof.
NO20093592L (en) Medication for the treatment of diabetes
Zhang et al. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
Reynolds et al. Individualizing warfarin therapy
ATE516300T1 (en) NEUROMEDIN-U RECEPTOR AGONISTS AND THEIR USE
WO2007024555A3 (en) Electronic personal health record system
WO2009057119A3 (en) Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
Davies et al. An inherited variant in the gene coding for vitamin D‐binding protein and survival from cutaneous melanoma: a B io G eno MEL study
Hankey et al. Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial
Kreutz et al. Cytochrome P450 3A4* 22, PPAR-α, and ARNT polymorphisms and clopidogrel response
Pramyothin et al. Type 2 diabetes in children and adolescents on atypical antipsychotics
Gallagher et al. Contrast-induced nephropathy in primary percutaneous coronary intervention
Hajjij et al. The impact of diabetes mellitus on outcomes of endoscopic sinus surgery: a nested case‐control study
Maiese Diabetic stress: new triumphs and challenges to maintain vascular longevity
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application